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Abstract
BACKGROUND: Alzheimer's disease (AD) and prion diseases such as sporadic Creutzfeldt-Jakob
disease (sCJD) share common features concerning their molecular pathogenesis and neuropathological
presentation and the coexistence of AD and CJD in patients suggest an association between the
deposition of the proteolytically processed form of the amyloid precursor protein, beta-amyloid (Abeta),
which deposits in AD, and the abnormal form of the prion protein, PrP(Sc), which deposits in sCJD.
METHODS: We have characterized sCJD patients (n = 14), AD patients (n = 5) and nondemented
controls (n = 5) with respect to the deposition of PrP(Sc) and Abeta morphologically, biochemically and
genetically and correlated these findings to clinical data. RESULTS: sCJD-diseased individuals with
abundant deposits of Abeta present with a specific clinicopathological profile, defined by higher age at
disease onset, long disease duration, a genetic profile and only minimal amounts of PrP(Sc) in the
cerebellum. CONCLUSION: The co-occurrence of pathological changes typical for sCJD and AD in
combination with the inverse association between accumulation of Abeta and PrP(Sc) in a subgroup of
sCJD patients is indicative of common pathways involved in the generation or clearance of Abeta and
PrP(Sc) in a subgroup of sCJD patients.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Neurodegenerative Dis  
 DOI: 10.1159/000121389 
 Association between Deposition of Beta-Amyloid 
and Pathological Prion Protein in Sporadic 
Creutzfeldt-Jakob Disease 
 Laura Debatin a    Johannes Streffer b    Markus Geissen c    Jakob Matschke c    
Adriano Aguzzi a    Markus Glatzel a, c 
 a  Institute of Neuropathology, and  b  Division of Psychiatry Research, University Hospital Zurich,  Zurich , Switzerland;
 c  Institute of Neuropathology, University Medical Center Hamburg-Eppendorf,  Hamburg , Germany 
accumulation of  A  and PrP Sc in a subgroup of sCJD patients 
is indicative of common pathways involved in the genera-
tion or clearance of  A  and PrP Sc in a subgroup of sCJD pa-
tients.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 In a subset of neurodegenerative diseases, deposition 
of abnormally processed proteins in the central nervous 
system constitutes the hallmark morphological charac-
teristic. Alzheimer’s disease (AD) and sporadic Creutz-
feldt-Jakob disease (sCJD) are prototypes of nontrans-
missible (AD) and transmissible (sCJD) cerebral pro-
teinopathies  [1–3] . In sCJD, generation or deposition of 
PrP Sc , a misfolded isoform of the glycosylphosphati-
dylinositol-anchored, physiologically expressed prion 
protein (PrP C ), results in neurodegeneration. In AD, pro-
teolytic processing of the amyloid precursor protein 
(APP) by   - and   -secretases generates a peptide termed 
  -amyloid (A  ). A  is mainly composed of the shorter 
A  40 and the longer A  42 , the latter representing the neu-
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 Abstract 
 Background: Alzheimer’s disease (AD) and prion diseases 
such as sporadic Creutzfeldt-Jakob disease (sCJD) share 
common features concerning their molecular pathogenesis 
and neuropathological presentation and the coexistence of 
AD and CJD in patients suggest an association between the 
deposition of the proteolytically processed form of the amy-
loid precursor protein,   -amyloid (A  ), which deposits in AD, 
and the abnormal form of the prion protein, PrP Sc , which de-
posits in sCJD.  Methods: We have characterized sCJD pa-
tients (n = 14), AD patients (n = 5) and nondemented controls 
(n = 5) with respect to the deposition of PrP Sc and A  mor-
phologically, biochemically and genetically and correlated 
these findings to clinical data.  Results: sCJD-diseased indi-
viduals with abundant deposits of  A  present with a spe-
cific clinicopathological profile, defined by higher age at dis-
ease onset, long disease duration, a genetic profile and only 
minimal amounts of PrP Sc in the cerebellum.  Conclusion: 
The co-occurrence of pathological changes typical for sCJD 
and AD in combination with the inverse association between 
 Received: May 7, 2007 
 Accepted after revision: October 31, 2007 
 Published online: March 18, 2008 D i s e a s e s
 Markus Glatzel 
 Institute of Neuropathology, University Medical Center Hamburg-Eppendorf 
 Martinistrasse 52,  DE–20246 Hamburg (Germany) 
 Tel. +49 40 42 803 2218, Fax +49 40 42 803 4929
E-Mail m.glatzel@uke.uni-hamburg.de 
 © 2008 S. Karger AG, Basel
1660–2854/08/0000–0000$24.50/0 
 Accessible online at:
www.karger.com/ndd 
 L.D. and J.S. contributed equally to this work. 
 Debatin /Streffer /Geissen /Matschke /
Aguzzi /Glatzel 
Neurodegenerative Dis2
rotoxic species. Although the two diseases are clinically 
and epidemiologically diverse, AD presenting as a slowly 
progressing disease, affecting one third of octogenarians, 
sCJD presenting with a rapidly progressing course, af-
fecting one individual per million per year, there is con-
siderable neuropathological and pathophysiological over-
lap  [4–7] . Both diseases are caused by extracellular depo-
sition of respective proteins in the form of amyloid and 
the generation of PrP Sc and A  leads to neurodegenera-
tion. Furthermore, PrP immunoreactivity can be found 
within A  plaques and several studies on AD and sCJD 
patients have reported combinations of pathological fea-
tures typical for AD and sCJD  [8–11] . Evidence for yet 
undefined common molecular mechanisms for both dis-
eases comes from studies demonstrating common genet-
ic risk factors: homozygosity for valine or methionine on 
a polymorphism within the gene encoding the prion pro-
tein ( PRNP codon 129), a known risk factor for the devel-
opment of sCJD, seems to constitute a risk factor for AD 
 [12, 13] . The status of the latter-mentioned polymorphism 
has been shown to modulate A  deposition during aging 
 [14] . Recent in vitro and in vivo studies show that PrP C 
levels may control A  formation  [15, 16] , whereas other 
studies have postulated similar mechanisms of seeded 
protein aggregation for A  and PrP Sc  [17] .
 The goal of our study was to further investigate puta-
tive interactions of A  and PrP Sc in sCJD patients. To this 
extend, we analyzed PrP Sc ,   -site APP-cleaving enzyme 
(BACE), A  40 and A  42 expression in patients suffering 
from sCJD or AD, and in nondemented control patients 
using immunohistochemistry, Western blot analysis and 
ELISA for respective proteins. In identical patient co-
horts, we collected clinical data, performed genetic anal-
ysis of disease-associated genes and correlated this infor-
mation to biochemical data. 
 Materials and Methods 
 Patients 
 All patients were referred to the Swiss National Reference Cen-
ter for Prion Diseases. The definite diagnosis of sCJD was estab-
lished according to the WHO criteria  [18] , whereas the definite 
diagnosis of AD was made according to the criteria of the Con-
sortium to Establish a Registry for Alzheimer’s Disease  [19] . 
 Samples were processed according to established guidelines 
regarding safety and ethics.  Table 1 summarizes the demograph-
ic characteristics of these patients.
 Immunohistochemistry 
 Brain tissue (frontal cortex) was fixed with 4% buffered for-
malin, inactivated by 98% formic acid treatment for 1 h, and em-
bedded in paraffin (tissue specimens from nondemented patients 
were formalin fixed only). Sections (3   m) were subjected to con-
ventional staining and to immunostaining for A  protein (A4, 
Sigma) and PrP (monoclonal antibody 3F4) according to standard 
protocols  [20] . 
 Neuropathological Methods 
 For quantification of the A  load, the frontal cortex was im-
munostained for A  protein and 3 representative regions were 
analyzed by quantifying the area immunoreactive for A  as a 
 percentage of the total area for each image with the analySIS  3.0 
program (Soft Imaging System GmbH, Münster, Germany) using 
published methods  [21] .
 Western Blot Analysis 
 Brain homogenates were treated with proteinase K where in-
dicated (specific activity of 41.3 U/mg; Roche, Basel, Switzerland) 
for 30 min at 37 ° C with a concentration of 0.03 U (40   g/ml sam-
ple). Total protein (50   g, measured prior to proteinase K treat-
ment) was electrophoresed through an SDS-PAGE gel (12%). Pro-
teins were transferred to nitrocellulose by wet blotting. Mem-
branes were blocked with Tris/HCl-buffered saline/Tween 20 
containing 5% top block, pH 7.4 (Sigma), incubated with antibod-
ies to PrP (3F4; Signet, Dedham, Mass., USA; 1: 2,000) or BACE 
[anti-BACE/Asp2 (CT); ProSci, Poway, Calif., USA; 1: 500] and vi-
sualized by enhanced chemiluminescence (Amersham Biosci-
ences). Relative quantification of the signal was performed em-
Table 1. Demographic characteristics and classification of patients studied by immunohistochemistry, Western blot for PrPSc, ELISA 
for A40, A42, CJD and AD-related genetic risk factors
A CNS level n M:F 
ratio
Mean age at
onset, years
Disease dura-
tion, months
4 allele 
%
PRNP codon 129 PrPSc type Mutations
mm mv vv 1 2 PRNP PSEN1 PSEN2 APP
CJD
High A42 6 3:3 75.285.1 10.189.4 50 3 2 1 3 3 – – – –
Low A42 8 5:3 67.789.3 3.882.2 12.5 7 0 1 7 1 a a a a
AD 5 2:3 81.087.5 a 40 2 2 1 b b a a a a
Controls 5 3:2 74.484.2 b 40 3 2 0 b b a a a a
CNS = Central nervous system. a Not tested. b Not applicable. 
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ploying a VersaDoc 5000 imaging station. To quantify PrP Sc , se-
rial dilutions of an identical standard sCJD brain homogenate (33, 
16.5, and 8.25   g of protein) were used on each Western blot to 
generate a standard curve according to published protocols  [22] .
 ELISA Quantification of A  Peptides 
 For extraction of formic acid-soluble A  , a 10% homogenate 
was prepared in 70% formic acid using a RiboLyser (Hybaid, Ash-
ford, UK). Following a centrifugation for 15 min at 16,000  g at 
4 ° C, supernatants were neutralized with a  ! 20 excess of 1  M 
Tris.
 Levels of  A  1–42 and  A  1–40 in the central nervous system of 
sCJD, AD and control cases were measured analyzing brain ho-
mogenates (100   l) with a high-sensitivity ELISA for the  A  1–42 
peptide (Innotest  A  1–42 , high-sensitivity test, Innogenetics, 
Gent, Belgium) and with ELISA for the  A  1–40 peptide (The Ge-
netics Company, Schlieren, Switzerland) according to manufac-
turer’s instructions. Samples were analyzed in duplicates and tests 
were performed twice.
 Genetic Analysis 
 Genomic DNA was extracted from whole blood or brain tissue 
using standard protocols. Mutation screening was performed by 
direct sequencing of both strands of PCR-amplified coding exons 
of presenilin 1 (PSEN1; exons 2–12), presenilin 2 (PSEN2; exons 
3–12), and APP (exons 16 and 17), and the single coding exon of 
 PRNP according to published protocols  [23] . Apolipoprotein E 
genotypes were assessed using a LightCycler TM (Roche Diagnos-
tics Corporation) according to published protocols  [24] . 
 Results 
 High Levels of A  42 in a Subgroup of sCJD Patients 
 In order to quantify levels of A  in frontal cortices, we 
analyzed A  42 and A  40 amounts by ELISA. While A  40 
brain loads, ranging between 20 and 25 pg/g wet brain in 
all groups, revealed uniform levels in sCJD patients [n = 
14, mean 24.8 pg/g wet brain, standard deviation (SD) 1.9 
pg/g wet brain, data not shown], we found a significant 
increase in A  42 in a subset of sCJD patients (n = 14, mean 
79.9 pg/g wet brain, SD 88.3 pg/g wet brain). In order to 
compare neuropathological, biochemical, genetic and 
clinical data, we decided to group sCJD patients into 2 
groups. The first group of patients (n = 6) showed cortical 
A  42 levels ranging from 80 to 193 pg/g wet brain (n = 6, 
mean 170.8 pg/g wet brain, SD 54.2 pg/g wet brain); this 
cohort was termed ‘high A  42 ’. The second group of pa-
tients (n = 8) did not show significant A  42 loads (below 
18 pg/g wet brain) ( fig. 1 A). These sCJD patients consti-
tuted the sCJD cohort with ‘low A  42 ’ (n = 8, mean 11.8 
pg/g wet brain, SD 2.6 pg/g wet brain). We compared A  42 
and A  40 amounts in frontal cortices of sCJD patients to 
those of clinically and neuropathologically confirmed 
AD patients and age-matched nondemented control pa-
tients. Similarly to sCJD patients, levels of A  40 were low 
in both groups (n = 10, mean 21.6 pg/g wet brain, SD 1.9 
pg/g wet brain, 5 samples were not analyzed for A  40 , data 
not shown). As expected, A  42 levels were high in the AD 
group (n = 5, mean 122.5 pg/g wet brain, SD 28.6 pg/g wet 
brain) and low in nondemented controls (n = 5, mean 22.3 
pg/g wet brain, SD 24.5 pg/g wet brain).
 We further investigated deposition of A  in the above-
mentioned cohorts by quantifying the amount of A  im-
munohistochemically. sCJD patients categorized in the 
high A  42 group showed abundant deposits of A  in the 
form of diffuse and neuritic, rarely cotton wool plaques 
(n = 6, mean 10.6% of investigated area occupied by im-
munoreactivity for A  , SD 9.5%;  fig. 1 B), whereas we 
could only detect scarce or no deposits of A  in sCJD pa-
tients categorized in the low A  42 group (n = 8, mean 
1.0% of investigated area occupied by immunoreactivity 
for A  , SD 1.2%). As anticipated, AD patients harbored 
extensive A  deposits mainly in the form of neuritic 
plaques ( fig. 1 C; n = 5, mean 10.6% of investigated area 
occupied by immunoreactivity for A  , SD 6.1%) and non-
demented controls exhibited limited or no A  deposits 
(n = 5, mean 0.2% of investigated area occupied by im-
munoreactivity for A  , SD 0.5%).
 No Influence of CJD- or AD-Associated Mutations 
 Both CJD and AD may be inherited in an autosomal 
dominant fashion. In the case of AD, mutations in the 
genes encoding APP, PSEN1 and PSEN2 have been shown 
to be associated with genetic AD, whereas mutations in 
 PRNP are accountable for genetic sCJD. Analysis of APP, 
PSEN1, PSEN2, and  PRNP did not reveal any pathogenic 
mutations in the subgroup of patients characterized by 
high A  42 levels ( table 1 ).
 sCJD Patients with High A  42 Are Genetically Diverse 
 The development of AD and sCJD is modulated by ge-
netic risk factors such as homozygosity for methionine on 
polymorphic codon 129 of  PRNP in the case of sCJD, or 
the presence of at least one allele of apolipoprotein E   4 
in the case of AD  [25] . Patients of the high A  42 group 
were more likely to carry the uncommon polymorphism 
 PRNP 129 valine/valine or methionine/valine. Of the 6 
sCJD patients belonging to the high A  42 group, 3 were 
methionine homozygotes, 2 were valine homozygotes 
and 1 was heterozygous. Of the 8 sCJD patients belonging 
to the low A  42 group, 7 were methionine homozygotes 
and 1 was a valine homozygote ( table 1 ). Furthermore, 
sCJD patients of the high A  42 group were more likely to 
carry a least one allele of apolipoprotein E   4 [50% apoli-
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poprotein E   4 carriers in the high A  42 group (n = 6), 
compared to 12.5% apolipoprotein E   4 carriers in the 
low A  42 group (n = 8)]. 
 sCJD Patients with Abundant A  Harbor Low 
Amounts of PrP Sc 
 We have recently developed a method that enables us 
to compare the PrP Sc load in defined central nervous sys-
tem regions of CJD patients  [22] . Using this method, 
termed PrP Sc profiling, we compared PrP Sc loads of sCJD 
patients belonging to the above-mentioned groups (high 
and low A  42 ). This analysis showed that patients belong-
ing to the high A  42 group (n = 5, in one individual this 
analysis was not possible due to insufficient sampling) 
display significantly less PrP Sc when compared to sCJD 
patients belonging to the low A  42 group (n = 8) ( fig. 2 ). 
A
High A42 Low A42
CJD AD Control
PrP
100 μm
100 μm
100 μm
100 μm
100 μm
100 μm
100 μm
100 μm
C
a b c d
e f g h
 Fig. 1. Increase in cortical A  in a subset of sCJD patients.  A For-
mic acid-treated brain homogenates of the frontal cortex were 
analyzed using sandwich ELISA for the presence of formic acid-
soluble A  40  (data not shown) and A  42 peptide. All sCJD cases 
were compared to AD patients/nondemented controls and classi-
fied according to A  42 concentrations in high ( 1 80 pg/g) and low 
A  42 (below 18 ng/g). Results are means of duplicates and are ex-
pressed as picograms per gram wet brain weight. The black lines 
within the boxes represent medians; the boxes encompass 25th 
and 75th percentiles of the distribution, the circle represents an 
outlier. Similar results were obtained in two independent experi-
ments.  B Quantification of A  immunoreactivity in frontal cor-
tices as a percentage of the total area. The values represent the 
average of 3 representative regions. The black lines within the 
boxes represent medians; the boxes encompass 25th and 75th per-
centiles of the distribution, the diamond and asterisk represent 
outliers.  C Immunohistochemistry for A  and PrP of frontal cor-
tices (a, e = sCJD high A  42 ; b, f = sCJD low A  42 ; c, g = AD;
d, h = nondemented control). Abundant deposits of A  in the 
form of diffuse and neuritic plaques in e and g, no deposits of A  
in f and h. Synaptic depositions of PrP in a and b (scale bar repre-
sents 100   m). 
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These differences are visible in all central nervous system 
regions that were investigated, but are most prominent in 
the putamen, thalamus and cerebellum. 
 sCJD Patients with Abundant A  Present with a 
Particular Clinical Profile 
 Since sCJD patients belonging to the high A  42 group 
show particular neuropathological, genetic and biochem-
ical features, we were interested in the clinical presenta-
tion of these patients. We compared age of disease onset 
and disease duration between the above-mentioned co-
horts. Patients of the high A  42 group were on average 
74.7 years old (SD 5.5 years), whereas patients of the low 
A  42 group were younger (68.6 years, SD 8.7 years; p = 
0.070, Student’s t test). Disease durations were statisti-
cally significantly longer in the high A  42 group (10.1 
months, SD 9.4 months) when compared to the low A  42 
group (3.8 months, SD 2.2 months; p = 0.044, Student’s t 
test). There were no differences regarding female-to-male 
ratios between the groups (3/3 for the high A  42 group, 
3/5 for the low A  42 group). 
 No Significant Difference in Cortical   -Secretase 
Expression between Groups 
 Elevated BACE protein levels and increased BACE ac-
tivity have been shown to be a prominent feature in the 
central nervous system of AD patients  [26] . This finding 
is in line with the fact that BACE is involved in the gen-
eration of A   [27] . In an effort to further investigate mo-
lecular pathways underlying enhanced generation of A  
in the high A  42 group of sCJD patients, we quantified 
BACE expression by Western blot analysis in frontal cor-
tices in sCJD (n = 6) and AD patients (n = 2), and in con-
trols (n = 1) ( fig. 3 ). Although there was some heterogene-
ity in the expression of BACE between the groups, there 
was no significant difference in BACE expression be-
tween high A  42 and low A  42 sCJD patients. 
 Discussion 
 In a wide range of dementias, generation and subse-
quent deposition of abnormally processed proteins is 
thought to be causally involved in the pathophysiology of 
the disease and assessment of protein deposition can be 
employed as a diagnostic tool for the classification of 
these entities  [28] . AD and CJD are two examples of this 
group of diseases, where generation and deposition of ab-
normally processed proteins, PrP Sc in the case of sCJD 
and A  in the case of AD, are involved in the pathophys-
iology. Coexistence of AD-type neuropathology in sCJD 
has been repeatedly reported, yet the interpretation of 
these findings is highly controversial. Some investigators 
surmise unspecific age-related changes  [11] , others as-
sume that this points to similarities in the pathogenesis 
of AD and CJD  [29] . In this study, we characterized de-
position of A  in sCJD patients by immunohistochemis-
try, Western blotting, ELISA and genetic investigations. 
Using biochemical methods we were able to identify a 
subgroup of sCJD patients, which is defined by high ce-
rebral  A  42 loads. These patients were on average more 
than 6 years older than those with minimal or no depos-
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 Fig. 2. PrP Sc profiling reveals low amounts 
of PrP Sc in the high A  42  group. PrP Sc 
amounts for high A  42 (n = 5) and low 
A  42 (n = 8) were measured in 9 brain re-
gions (shown on the x-axis). Values for 
PrP Sc amounts are given in arbitrary units 
measured in relation to a PrP Sc standard. 
High A  42 patients harbor low amounts of 
PrP Sc , especially in the putamen, thalamus 
and cerebellum. The black lines within the 
boxes represent medians; the boxes en-
compass 25th and 75th percentiles of the 
distribution, the diamonds and asterisks 
represent outliers.  
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its of  A  42 , presented with significantly longer disease 
durations, were more likely to carry an uncommon poly-
morphism on  PRNP codon 129 or deposit PrP Sc type 2 
 [30] and had a high likelihood to carry at least one allele 
of apolipoprotein E   4. Interestingly, these patients har-
bor only minimal amounts of PrP Sc in the cerebellum. 
This clinicopathological signature suggests that this 
group of patients represents a subgroup of sCJD. 
 A study focusing on the assessment of genetic profiles 
of sCJD demonstrated that the apolipoprotein E   4 allele 
is an independent risk factor for developing sCJD  [31, 32] . 
In this study, we provide evidence that the apolipoprotein 
E   4 status may be linked to the development of a subtype 
of sCJD. The above-mentioned study did not investigate 
A  loads in apolipoprotein E   4-positive sCJD patients. 
One could hypothesize that patients identified by van 
 Everbroeck et al.  [32] belong to the subgroup of sCJD 
 patients characterized by abundant A  and scarce PrP Sc 
deposits. 
 A study focusing on the influence of PrP C expression 
on A  plaque formation suggested that overexpression of 
PrP C promotes A  plaque formation  [15] . Given the fact 
that PrP C expression is unchanged during the course of 
prion disease  [33] , PrP C upregulation is an unlikely expla-
nation for enhanced A  deposition in certain sCJD pa-
tients. Since accumulation of malprocessed proteins in 
the brain is the result of the differential between its de 
novo generation and its clearance, it is conceivable that 
A  deposition in sCJD may be the result of a saturation 
of common clearance mechanisms  [34, 35] . This hy-
pothesis is supported by a wealth of data suggesting that 
similar processes of protein degradation are in place for 
PrP Sc and A   [36–38] .
 In an attempt to delineate possible molecular path-
ways explaining the abundant generation of A  42 in a 
subset of sCJD patients, we measured central nervous 
system expression of   -secretase, a key protease for the 
generation of A   [27] . Several studies have shown that
  -secretase activity and protein expression are increased 
in the cortex of patients suffering from AD  [26, 39, 40] . 
Furthermore, BACE activity seems to be increased in the 
cerebrospinal fluid of sCJD patients  [41] . The fact that we 
did not find any significant differences in BACE expres-
sion is in agreement with published studies and may in-
dicate alternative pathways for A  generation in these 
patients  [41] . 
 The group of sCJD patients with high cerebral levels 
of A  42 showed minimal deposits of PrP Sc . PrP Sc profil-
ing allowed us to directly compare PrP Sc levels between 
sCJD cohorts  [22] . PrP Sc levels showed the most drastic 
differences in the cerebellum. PrP Sc levels in low A  42 
patients uniformly showed high cerebellar PrP Sc loads, 
whereas PrP Sc levels in high A  42 patients uniformly 
showed low or nondetectable cerebellar PrP Sc levels. In-
terestingly, cerebellar involvement is a rarity in AD  [42] . 
It has been speculated that the descriptive classification 
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 Fig. 3. BACE expression is not elevated in the frontal cortex of sCJD patients.  A Western blot analysis for the 
assessment of cortical   -secretase levels was performed in subsets of sCJD patients, AD patients and nonde-
mented controls.  B Box plot showing quantification of   -secretase expression. Relative signal intensities of   -
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of AD may camouflage CJD  [43] . Although one could ar-
gue that the subgroup of sCJD we have identified could 
have been misdiagnosed as AD, thus supporting the 
above-mentioned hypothesis, the sCJD typical clinical 
presentation of these patients argues against the theory 
that sCJD is commonly misdiagnosed as AD. Taking into 
account that the majority of cerebral proteinopathies are 
characterized by deposition of more than one abnormal-
ly processed protein  [28] , neuropathological diagnosis of 
dementia should only be carried out in centers equipped 
to monitor deposition of all disease-associated proteins. 
 In conclusion, the present study provides evidence for 
the existence of a subgroup of sCJD characterized by 
abundant A  42 deposits, high age at onset of disease, a 
specific genetic profile and only marginal deposits of 
PrP Sc . These data are in line with common molecular 
mechanisms leading to the deposition of A  and PrP Sc . 
Their delineation will be the focus of future studies. The 
fact that this newly defined group of patients harbors 
only minimal amounts of PrP Sc is intriguing. On the one 
hand, this represents a challenge to neuropathologists, 
and on the other hand, the possibility that minimal
PrP Sc deposits may go undetected could lead to the mis-
diagnosis of AD. 
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